{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:32:56Z","timestamp":1787668376700,"version":"build-2736575974"},"reference-count":17,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    Alectinib is a potent and selective orally active tyrosine kinase inhibitor used for anaplastic lymphoma kinase-positive non-small cell lung cancer, which has a better safety profile than other inhibitors of anaplastic lymphoma kinase. We report a case of a mixed pattern of acute interstitial nephritis and acute tubular necrosis proven by renal biopsy upon starting alectinib therapy.\n                    <jats:bold>Case report:<\/jats:bold>\n                    A 68-year-old man with diabetes, hypertension, and dyslipidaemia, diagnosed with anaplastic lymphoma kinase-positive non-small cell lung cancer stage IV, had 27 days previously started alectinib 600\u2005mg twice daily. He presented at the emergency room due to vomiting, nausea, and more dyspnoea than usual. A high creatinine level and metabolic imbalances were detected in laboratory tests.\n                    <jats:bold>Management and outcomes:<\/jats:bold>\n                    After a diagnosis of acute renal failure, the patient was admitted to hospital. Nephrotoxic drugs were suspended, and haemodialysis was required. After dismissing other causes, a probable diagnosis of acute interstitial nephritis due to alectinib was established. Corticotherapy was initiated and renal function returned to baseline levels. Renal biopsy showed a mixed pattern of acute interstitial nephritis and acute tubular necrosis. The patient was discharged, and alectinib therapy was modified to lorlatinib. No polymorphisms were found in a pharmacogenetic test. After 10 months with lorlatinib, renal function remains stable.\n                    <jats:bold>Discussion:<\/jats:bold>\n                    The relationship between acute renal failure and alectinib initiation is considered probable in this patient. Although it is an adverse effect reported in less than 1% of cases, it would be advisable to monitor renal function in this kind of patient.\n                  <\/jats:p>","DOI":"10.1177\/10781552231167808","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T03:23:45Z","timestamp":1680751425000},"page":"403-407","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Alectinib \u2013 induced acute renal failure"],"prefix":"10.1177","volume":"32","author":[{"given":"Elena","family":"Prado-Mel","sequence":"first","affiliation":[{"name":"Hospital Pharmacy Department, Virgen del Roc\u00edo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6757-3247","authenticated-orcid":false,"given":"Pablo","family":"Ciudad-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Department, Virgen del Roc\u00edo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"S\u00e1nchez-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Department, Virgen de las Nieves Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila Abdel-Kader","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Department, Virgen del Roc\u00edo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"National Cancer Institute. Surveillance epidemiology and end results program. https:\/\/seer.cancer.gov\/statfacts\/htm.l\/lungb.html."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25183"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0379-y"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.06.070"},{"key":"e_1_3_4_7_2","unstructured":"Alecensa (Alectinib) EMA label: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/1161169001\/FT_1161169001.pdf."},{"key":"e_1_3_4_8_2","first-page":"340","article-title":"Functional gene variants of CYP3A4","volume":"96","author":"Werk AN","year":"2014","unstructured":"Werk AN, Cascorbi I.Functional gene variants of CYP3A4. Clin PharmacolTher2014; 96: 340\u2013348. Epub 2014 Jun 13. PMID: 24926778.","journal-title":"Clin PharmacolTher"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omy009"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S136837"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-018-1849-y"},{"key":"e_1_3_4_12_2","first-page":"558","article-title":"Acute kidney injury in interstitial nephritis","volume":"25","author":"Caravaca-Font\u00e1n F","year":"2019","unstructured":"Caravaca-Font\u00e1n F, Fern\u00e1ndez-Ju\u00e1rez G, Praga M.Acute kidney injury in interstitial nephritis. CurrOpin Crit Care2019; 25: 558\u2013564. PMID: 31503026.","journal-title":"CurrOpin Crit Care"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu326"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2016.11.004"},{"key":"e_1_3_4_15_2","first-page":"310","article-title":"Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies","volume":"23","author":"Troxell ML","year":"2016","unstructured":"Troxell ML, Higgins JP, Kambham N.Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies. Adv AnatPathol2016; 23: 310\u2013329. PMID: 27403615.","journal-title":"Adv AnatPathol"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28478"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70362-6"},{"key":"e_1_3_4_18_2","first-page":"239","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.A method for estimating the probability of adverse drug reactions. Clin PharmacolTher1981; 30: 239\u2013245. PMID: 7249508.","journal-title":"Clin PharmacolTher"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231167808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231167808","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231167808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:11Z","timestamp":1777688891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231167808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/10781552231167808"],"URL":"https:\/\/doi.org\/10.1177\/10781552231167808","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}